Charles River provides lab research services and animal models for drug development.
Charles River Laboratories International, Inc. (CRL) is expected to report earnings on Wednesday, November 4, 2026, after the close. Estimated release time 07:15 ET. Consensus EPS estimate is $2.96.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $2.74 | $3.02 | +10.2% | $1.00B |
| 2026-05-07 | FY2026 Q1 | $1.96 | $2.06 | +5.1% | $995.83M |
| 2026-02-18 | FY2025 Q4 | $2.33 | $2.39 | +2.6% | $994.23M |
| 2025-11-05 | FY2025 Q3 | $2.32 | $2.43 | +4.7% | $1.00B |
| 2025-08-06 | FY2025 Q2 | $2.50 | $3.12 | +24.8% | $1.03B |
| 2025-05-07 | FY2025 Q1 | $2.06 | $2.34 | +13.6% | $984.17M |
| 2025-02-19 | FY2024 Q4 | $2.50 | $2.66 | +6.4% | $1.00B |
| 2024-11-06 | FY2024 Q3 | $2.42 | $2.59 | +7.0% | $1.01B |
CRL has beaten consensus EPS in 8 of its last 8 reported quarters.
Highlights from CRL's Aug 5 report: EPS of $3.02 — a beat vs the $2.74 estimate (+10%); revenue of $1B — a beat vs the $977M consensus (+3%). Focus now shifts to biotech demand and DSA bookings.
See CRL on the live calendar →